AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36547975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral β-glucan during the first 5 weeks of vaccine priming (group 2)
Number of subjects: 107
Study 36547975 — intervention group
Group type: COMPARATOR
Intervention: GD2/GD3 vaccine without β-glucan (group 1)
Number of subjects: 107
Study 36547975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral β-glucan during vaccine boost (both groups)
Number of subjects: 107
Study 36547975 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GD2 IgG1 titer of 230 ng/mL or greater by week 8
Number of subjects: 107
Study 36547975 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of antibody titer with dectin-1 SNP
Number of subjects: 107
Study 36547975 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroconversion rates
Number of subjects: 107
Study 36547975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-related toxic effects
Number of subjects: 107
Study 36548028 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Medicine System (DMS)
Number of subjects: 46
Study 36548028 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 46
Study 36548042 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's social information processing (SIP)
Number of subjects: 0
Study 36548078 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition blocking the devaluation of medical reassurance
Number of subjects: 0
Study 36548078 — intervention group
Group type: COMPARATOR
Intervention: Control groups (depressed and healthy people)
Number of subjects: 0
Study 36548143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG) and health education during eight ANC visits
Number of subjects: 288
Study 36548143 — intervention group
Group type: COMPARATOR
Intervention: Usual care consisting of four ANC visits and two USG
Number of subjects: 288
Study 36548225 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of any active antibiotic
Number of subjects: 304
Study 36548225 — intervention group
Group type: COMPARATOR
Intervention: 14-day course of any active antibiotic
Number of subjects: 304
Study 36548281 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening test for albuminuria using a conventional urine collection device
Number of subjects: 15000
Study 36548281 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening test for albuminuria using an innovative smartphone application
Number of subjects: 15000
Study 36548281 — intervention group
Group type: EXPERIMENTAL
Intervention: Central screening facility for elaborate screening for CKD and CVD risk factors (following positive home test)
Number of subjects: 15000
Study 36548338 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Aerobic Exercise Protocol (SAEP)
Number of subjects: 38
Study 36548338 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Exercise Prescription (UCEP)
Number of subjects: 38
Study 36548444 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (single dose of praziquantel)
Number of subjects: 125
Study 36548444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense treatment (4 repeated doses of praziquantel at 2-week intervals)
Number of subjects: 125
Study 36548444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 125
Study 36548448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge intervention (ChooseWell 365)
Number of subjects: 487
Study 36548448 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 487
Study 36548543 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study 36548927 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epcoritamab
Number of subjects: 157
Study 36549084 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA patients with recurrent cardiovascular events (CVE)
Number of subjects: 86
Study 36549084 — intervention group
Group type: COMPARATOR
Intervention: Severe OSA patients without recurrent cardiovascular events (CVE)
Number of subjects: 86
Study 36549090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry parameters (baseline pupillary diameter, PD; PD variations, PDV; pupillary constriction velocity, PCV)
Number of subjects: 50
Study 36549308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg per kg of bodyweight, maximum 25 mg)
Number of subjects: 578
Study 36549308 — intervention group
Group type: COMPARATOR
Intervention: Control (no thrombolysis)
Number of subjects: 578
Study 36549308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 578
Study 36549308 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 578
Study 36549320 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-based sequential quadruple therapy for 14 days (EAML14); esomeprazole 40 mg and amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, metronidazole 500 mg, and levofloxacin 250 mg for 7 days, all twice-daily.
Number of subjects: 560
Study 36549320 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-based quadruple therapy for 10 days (BQ10); esomeprazole 40 mg twice daily, bismuth tripotassium dicitrate 300 mg four times a day, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day.
Number of subjects: 560
Study 36549320 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin-based sequential quadruple therapy (EAML14) and Bismuth-based quadruple therapy (BQ10)
Number of subjects: 560
Study 36549342 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Positive training (n=21)
Number of subjects: 45
Study 36549342 — intervention group
Group type: COMPARATOR
Intervention: Balanced training (n=24)
Number of subjects: 45
Study 36549342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 36549347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab with radiation and cisplatin (arm B)
Number of subjects: 891
Study 36549347 — intervention group
Group type: COMPARATOR
Intervention: Radiation and cisplatin without cetuximab (arm A)
Number of subjects: 891
Study 36549722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enrollers (DSD enrolment after <6 months on ART)
Number of subjects: 32197
Study 36549722 — intervention group
Group type: COMPARATOR
Intervention: Established enrollers (DSD enrolment after ≥6 months on ART)
Number of subjects: 32197
Study 36549722 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enrollers
Number of subjects: 32197
Study 36549723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-conducted medication reconciliation
Number of subjects: 0
Study 36549727 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended HPV genotyping (pool_1: HPV 16, 18, 45; pool_2: HPV 16, 18, 45, 31, 33, 35, 52, 58)
Number of subjects: 2014
Study 36549727 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Inspection with Acetic Acid (VIA)
Number of subjects: 2014
Study 36549727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology
Number of subjects: 2014
Study 36549727 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended HPV genotyping
Number of subjects: 2014
Study 36549727 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA
Number of subjects: 2014
Study 36549740 — intervention group
Group type: EXPERIMENTAL
Intervention: Free access to a comprehensive list of essential medicines for 24 months
Number of subjects: 786
Study 36549741 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAYshop programme
Number of subjects: 130
Study 36549741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 36549747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 100
Study 36549747 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 100
Study 36549749 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Number of subjects: 400
Study 36549749 — intervention group
Group type: COMPARATOR
Intervention: Active attention control (text message reminders)
Number of subjects: 400
Study 36549781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO+IPI)
Number of subjects: 139
Study 36549781 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 139
Study 36549786 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) for 12 weeks, training twice daily using a threshold inspiratory muscle trainer
Number of subjects: 26
Study 36549786 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 26
Study 36549898 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily, increased to 20 mg daily after 4 weeks if no toxicity
Number of subjects: 67
Study 36550063 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-min educational video on aneuploidy screening
Number of subjects: 286
Study 36550063 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling (Control)
Number of subjects: 286
Study 36550396 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual dietary behavior intervention
Number of subjects: 0
Study 36550417 — intervention group
Group type: EXPERIMENTAL
Intervention: Supermaximum recession resection (group S)
Number of subjects: 54
Study 36550417 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented recession by lateral rectus muscle elongation with an autograft from the resected medial rectus muscle (group E)
Number of subjects: 54
Study 36550417 — intervention group
Group type: COMPARATOR
Intervention: Both groups (S and E)
Number of subjects: 54
Study 36550428 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional cycles of Lutathera® (7.4 GBq infusion each, separated by 8 weeks)
Number of subjects: 146
Study 36550428 — intervention group
Group type: COMPARATOR
Intervention: No treatment (active surveillance)
Number of subjects: 146
Study 36550451 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Toothbrush and Smart Mirror (STM) system
Number of subjects: 42
Study 36550451 — intervention group
Group type: COMPARATOR
Intervention: Conventional Tooth Brushing Instruction (TBI)
Number of subjects: 42
Study 36550466 — intervention group
Group type: EXPERIMENTAL
Intervention: Refusal documentation method
Number of subjects: 7
Study 36550466 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine refusal
Number of subjects: 7
Study 36550559 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL crystalloid fluid bolus (FB) administered over 30 min
Number of subjects: 130
Study 36550559 — intervention group
Group type: COMPARATOR
Intervention: non-interventional follow-up (FU) for 2 hours
Number of subjects: 130
Study 36550559 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL crystalloid fluid bolus (FB)
Number of subjects: 130
Study 36550559 — intervention group
Group type: COMPARATOR
Intervention: non-interventional follow-up (FU)
Number of subjects: 130
Study 36550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (12.5 mg subcutaneous once every 4 weeks)
Number of subjects: 350
Study 36550562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 36550562 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Number of subjects: 350
Study 36550564 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT group (34 women)
Number of subjects: 54
Study 36550564 — intervention group
Group type: COMPARATOR
Intervention: EDU group (20 women)
Number of subjects: 54
Study 36550568 — intervention group
Group type: COMPARATOR
Intervention: Diastole-synchronized compressions/decompressions (DSCD) for 20 minutes in Study 1
Number of subjects: 54
Study 36550568 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastole-synchronized compressions/decompressions (DSCD) for 60 minutes, three times/week for three months in Study 2
Number of subjects: 54
Study 36550568 — intervention group
Group type: COMPARATOR
Intervention: Control session (simulated) in Study 1
Number of subjects: 54
Study 36550568 — intervention group
Group type: COMPARATOR
Intervention: Control period (without simulated sessions) in Study 2
Number of subjects: 54
Study 36550636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 0
Study 36550636 — intervention group
Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 0
Study 36550636 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE participants
Number of subjects: 0
Study 36550683 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg loading dose and then 6 mg/kg every 3 weeks) and Irinotecan (120 mg/m2 days 1 and 8 every 3 weeks)
Number of subjects: 21
Study 36551626 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX-2843
Number of subjects: 39
Study 36551626 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX-2843 with venetoclax
Number of subjects: 39
Study 36551677 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMITAL granules for oral suspension (20 mL, four times daily)
Number of subjects: 116
Study 36551677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 36551677 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMITAL granules for oral suspension
Number of subjects: 116
Study 36551718 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 32
Study 36552013 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (%VO2pred < 80%)
Number of subjects: 120
Study 36552013 — intervention group
Group type: COMPARATOR
Intervention: Control group (%VO2pred ≥ 80%)
Number of subjects: 120
Study 36552013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple logistic regression model
Number of subjects: 120
Study 36552120 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RTGT)
Number of subjects: 120
Study 36552120 — intervention group
Group type: COMPARATOR
Intervention: Therapist-assisted treadmill gait training (TTGT)
Number of subjects: 120
Study 36552120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RTGT and TTGT
Number of subjects: 120
Study 36553294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy
Number of subjects: 286
Study 36553294 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for SDB
Number of subjects: 286
Study 36553294 — intervention group
Group type: COMPARATOR
Intervention: No treatment for SDB
Number of subjects: 286
Study 36553313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (5 min audio recording focusing on breathing and nonjudgmental attention)
Number of subjects: 61
Study 36553313 — intervention group
Group type: COMPARATOR
Intervention: Control condition (5 min audio recording involving an unfocused attention task)
Number of subjects: 61
Study 36553313 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 61
Study 36553313 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study 36554485 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVE system (technology-based elderly care system)
Number of subjects: 165
Study 36554543 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg's rating of perceived exertion (BRPE) scale during treadmill walking
Number of subjects: 134
Study 36554543 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg's rating of perceived exertion (BRPE) scale during outdoor uphill cardio-trekking test (1 km CTT)
Number of subjects: 134
Study 36554543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-based, objective exercise-intensity parameters such as heart rate (HR)
Number of subjects: 134
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety in paediatric patients
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of preoperative anxiety
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Average postoperative pain at rest
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' age
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental trait anxiety
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender of parents
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous route for postoperative pain management
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anxiety in patients
Number of subjects: 0
Study 36554581 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender of children
Number of subjects: 0
Study 36554612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted judo program (90 min practice each week for 6 months)
Number of subjects: 40
Study 36554612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 40
Study 36554652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling wheelchair training for 30 min a day, 5 days a week, for 4 weeks
Number of subjects: 41
Study 36554652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling wheelchair training
Number of subjects: 41
Study 36554820 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic therapy with Johanna (good outcome)
Number of subjects: 2
Study 36554820 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic therapy with Sonja (poor outcome)
Number of subjects: 2
Study 36554830 — intervention group
Group type: EXPERIMENTAL
Intervention: FrenChILD-Index for moderate deprivation
Number of subjects: 986
Study 36554830 — intervention group
Group type: EXPERIMENTAL
Intervention: FrenChILD-Index for severe deprivation
Number of subjects: 986
Study 36554860 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based pulmonary rehabilitation
Number of subjects: 32
Study 36554860 — intervention group
Group type: COMPARATOR
Intervention: Traditional form of therapy (Control)
Number of subjects: 32
Study 36555879 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf neuromuscular electrical stimulation (NMES) program for 12 weeks
Number of subjects: 0
Study 36555879 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 0
Study 36555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg
Number of subjects: 83
Study 36555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg
Number of subjects: 83
Study 36555933 — intervention group
Group type: COMPARATOR
Intervention: Placebo→Rituximab 1000 mg
Number of subjects: 83
Study 36555933 — intervention group
Group type: COMPARATOR
Intervention: Placebo→Rituximab 500 mg
Number of subjects: 83
Study 36556365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage retrograde endoscopic stone removal during initial ERCP
Number of subjects: 123
Study 36556977 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerecis (Intact Fish Skin Graft)
Number of subjects: 0
Study 36556977 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 0
Study 36557750 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal microbiota with inhibitory activity
Number of subjects: 0
Study 36557750 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36560565 — intervention group
Group type: EXPERIMENTAL
Intervention: BC02 (BCG CpG DNA compound adjuvants system 02)
Number of subjects: 0
Study 36560565 — intervention group
Group type: COMPARATOR
Intervention: Recombinant Glycoprotein E of Varicella-Zoster Virus
Number of subjects: 0
Study 36560966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C pressurized intraperitoneal aerosolized chemotherapy (MMC-PIPAC) combined with systemic chemotherapy (FOLFIRI)
Number of subjects: 0
Study 36561174 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 600 μg/kg daily for 6 days
Number of subjects: 1206
Study 36561174 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 6 days
Number of subjects: 1206
Study 36561483 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld ultrasound-guided dynamic needle position technique
Number of subjects: 118
Study 36561483 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 118
Study 36561560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte cryopreservation
Number of subjects: 397
Study 36561560 — intervention group
Group type: COMPARATOR
Intervention: Non-returned patients
Number of subjects: 397
Study 36561560 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at freezing
Number of subjects: 397
Study 36561560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of a partner
Number of subjects: 397
Study 36561560 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of cancer
Number of subjects: 397
Study 36561560 — intervention group
Group type: COMPARATOR
Intervention: Personal reasons for not returning
Number of subjects: 397
Study 36561637 — intervention group
Group type: EXPERIMENTAL
Intervention: Central Executive Training (CET)
Number of subjects: 94
Study 36561714 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (E-Stim) for 1 hour daily for up to 14 days on both gastrocnemius muscles (GNMs)
Number of subjects: 32
Study 36561714 — intervention group
Group type: COMPARATOR
Intervention: Control group received no functional E-Stim device
Number of subjects: 32
Study 36561723 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior use of non-steroidal anti-inflammatory drugs
Number of subjects: 134
Study 36561723 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 134
Study 36561857 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Medication Adherence (IMA) intervention
Number of subjects: 604
Study 36561924 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended e-health intervention for exercising at home under remote supervision of a physiotherapist (PT)
Number of subjects: 22
Study 36562136 — intervention group
Group type: COMPARATOR
Intervention: MA (160 mg oral daily)
Number of subjects: 63
Study 36562136 — intervention group
Group type: EXPERIMENTAL
Intervention: MA + LNG-IUS (160 mg oral daily + LNG-IUS)
Number of subjects: 63
Study 36562609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined platinum-based chemotherapy with cetuximab treatment
Number of subjects: 56